Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

被引：0
|
作者：
Tomokazu Kishiki
Hiroaki Ohnishi
Tadahiko Masaki
Kouki Ohtsuka
Yasuo Ohkura
Jyunji Furuse
Takashi Watanabe
Masanori Sugiyama
机构：
[1] Kyorin University School of Medicine,Department of Surgery
[2] Kyorin University School of Medicine,Department of Laboratory Medicine
[3] Kyorin University School of Medicine,Department of Pathology
[4] Kyorin University School of Medicine,Department of Medical Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
Colorectal cancer; PTEN; MET; Anti-EGFR therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：749 / 757
页数：8
相关论文
共 50 条
  • [21] Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients
    Smith, D.
    Bosacki, C.
    Merrouche, Y.
    BULLETIN DU CANCER, 2009, 96 : S31 - S40
  • [22] Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations
    Voutsadakis, Ioannis A.
    PHARMACOGENOMICS, 2025,
  • [23] Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Xiaona Lu
    Yuyao Li
    Yue Li
    Xuemei Zhang
    Jia Shi
    Hai Feng
    Zhuo Yu
    Yueqiu Gao
    BMC Cancer, 23
  • [24] Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Lu, Xiaona
    Li, Yuyao
    Li, Yue
    Zhang, Xuemei
    Shi, Jia
    Feng, Hai
    Yu, Zhuo
    Gao, Yueqiu
    BMC CANCER, 2023, 23 (01)
  • [25] The secondary mutation of KRAS and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer
    Xia, X.
    Du, W.
    Zhu, Y.
    Bai, Y.
    Liu, M.
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (3-4) : 218 - 218
  • [26] Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
    Hsieh, Meng-Chiao
    Wu, Chun-Feng
    Chen, Chun-Wei
    Shi, Chung-Sheng
    Huang, Wen-Shih
    Kuan, Feng-Che
    SCIENTIFIC REPORTS, 2018, 8
  • [27] Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
    Meng-Chiao Hsieh
    Chun-Feng Wu
    Chun-Wei Chen
    Chung-Sheng Shi
    Wen-Shih Huang
    Feng-Che Kuan
    Scientific Reports, 8
  • [28] Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
    N Takahashi
    Y Yamada
    K Furuta
    Y Honma
    S Iwasa
    A Takashima
    K Kato
    T Hamaguchi
    Y Shimada
    British Journal of Cancer, 2014, 110 : 2716 - 2727
  • [29] HSA-MIR31-3P EXPRESSION AS A PREDICTOR OF ANTI-EGFR RESPONSE IN WILD-TYPE KRAS PATIENTS WITH METASTATIC COLORECTAL CANCER
    Laurent-Puig, P.
    Manceau, G.
    Bachet, J.
    Chibaudel, B.
    Liebaert, F.
    Bouche, O.
    Penault-Llorca, F.
    Diebold, M. D.
    Andre, T.
    Imbeaud, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 180 - 180
  • [30] Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
    Takahashi, N.
    Yamada, Y.
    Furuta, K.
    Honma, Y.
    Iwasa, S.
    Takashima, A.
    Kato, K.
    Hamaguchi, T.
    Shimada, Y.
    BRITISH JOURNAL OF CANCER, 2014, 110 (11) : 2716 - 2727
12345